Immune-Mediated Inflammatory Diseases and Other Comorbidities in Patients With Psoriasis: Baseline Characteristics of Patients in the AQUILES Study

Vanaclocha, F.; Crespo-Erchiga, Vicente; Jiménez‐Puya, R.; Puig, Luís; Sánchez‐Carazo, J.L.; Ferrán, Marta; Sancho, Cristina; Juliá, Berta; Cea‐Calvo, Luis; Marín-Jiménez, Ignacio; García‐Vicuña, Rosario

doi:10.1016/j.adengl.2014.11.012

Cited by 11 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Psoriasis has a profound negative impact on patients' quality of life and increases the risk for early mortality and prevalence of comorbidities, including cardiovascular disease, hypertension, hyperlipidemia, diabetes, and depression. [5][6][7] Complete or nearly complete clearance is now achievable with available biologic treatments targeting various cytokines involved in disease pathogenesis, namely interleukin (IL)-17, IL-23, and tumour necrosis factor (TNF)-a [8][9][10][11] ; however, the durability of response with many biologics is limited in clinical practice after 1-2 years due to loss of treatment effect over time. 12,13 IL-23, a key regulatory cytokine, is essential for pathogenic T helper 17 (Th17) cell differentiation, activation, and survival.…”

Section: Introductionmentioning

confidence: 99%

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis

Gooderham

Pinter

Ferris

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Risankizumab has demonstrated durable, high rates of efficacy in patients with moderate‐to‐severe plaque psoriasis as assessed by the achievement of relative Psoriasis Area and Severity Index (PASI) improvement and Dermatology Life Quality Index (DLQI) 0/1. Objectives The aim of this post hoc analysis is to assess the achievement of absolute PASI thresholds and related improvements in health‐related quality of life (HRQoL) in patients with moderate‐to‐severe plaque psoriasis treated with (i) risankizumab compared with ustekinumab, and (ii) long‐term (>52 weeks to 172 weeks) risankizumab. Methods Data from patients randomised to 150 mg risankizumab or 45 or 90 mg ustekinumab in replicate randomised controlled trials UltIMMa‐1 and UltIMMa‐2 were analysed for the achievement of absolute PASI thresholds PASI ≤ 3, PASI ≤ 1, and PASI = 0, time to achieve these thresholds, and combined PASI and DLQI endpoints. Data from pat ients initially randomised to risankizumab who continued on risankizumab in the open‐label extension study LIMMitless were analysed for the achievement of absolute PASI levels, mean DLQI scores, and DLQI 0/1. Results Significantly greater proportions of patients treated with risankizumab compared with ustekinumab achieved PASI ≤ 3, PASI ≤ 1, and PASI = 0, as well as combined endpoints for absolute PASI and DLQI [(PASI ≤ 3 and DLQI ≤ 5) or (PASI ≤ 1 and DLQI 0/1)]. The median time to first achieve PASI ≤ 3, PASI ≤ 1, and PASI = 0 was significantly lower for risankizumab‐treated patients compared with ustekinumab‐treated patients. Among patients treated with long‐term risankizumab, more than 90% achieved PASI ≤ 3 though week 172 and more than 80% achieved DLQI 0/1. Low absolute PASI scores corresponded with low mean absolute DLQI scores through week 172 of continuous risankizumab treatment. Conclusions Risankizumab treatment demonstrated high rates of rapid and durable efficacy as measured by absolute PASI thresholds and improvements in patient HRQoL.

show abstract

Section: Introductionmentioning

confidence: 99%

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis

Gooderham

Pinter

Ferris

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Ultimately, 14 studies met our inclusion criteria and were included in the systematic review. [11][12][13][14][15][16][17][18][19][20][21][22][23][24] The detailed search process is outlined in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

“…11,19,22,23 One study examined psoriasis patients in comparison to spondyloarthritis and inflammatory bowel disease patients. 24 When a given study presented analysis of uveitis in a psoriasis group and a PsA group, the participant data from the psoriasis group were used in this systematic review. Overall from the 14 studies included, 4 were cross-sectional designs, 6 were cohort studies, and 4 were case-control studies.…”

Section: Resultsmentioning

confidence: 99%

“…Ten studies presented findings on ocular abnormalities in psoriasis patients, 11,[13][14][15][16]19,[21][22][23][24] while 3 studies examined only uveitis among the patient population. 17,18,20 Four studies reported no cases of uveitis among psoriasis patients.…”

Section: Resultsmentioning

confidence: 99%

“…19,22 Three studies reported 2 subjects with uveitis where 1 had PsA and the other did not. 13,16,24 One study included 3 subjects with PsA, none of which had no evident ocular manifestations. 14 One study included 7 subjects with PsA, out of 101 psoriasis participants, where all 3 individuals who presented uveitis also had PsA.…”

Section: Prevalence Of Uveitis In Psoriasis Compared To Psamentioning

confidence: 99%

See 2 more Smart Citations

The Incidence and Prevalence of Uveitis in Psoriasis: A Systematic Review and Meta-Analysis

Lam

Steen

et al. 2020

J Cutan Med Surg

View full text Add to dashboard Cite

Background The systemic effects and comorbidities of psoriasis include ocular disorders, such as uveitis. Patients with psoriatic arthritis in particular have been demonstrated to have an elevated risk for developing uveitis. Presently, the risk of uveitis in psoriasis has yet to be fully elucidated and this systematic review seeks to address this gap. Objective To examine the prevalence and incidence of uveitis in psoriasis patients compared to non-psoriasis patients. Methods We conducted a systematic review search on MEDLINE, Embase, and CENTRAL electronic databases with no lower limit on year of publication. Results Fourteen articles met our inclusion criteria, with a total of 234 143 psoriasis subjects. Two studies found that participants with severe psoriasis were at a greater risk of uveitis than those with mild psoriasis. A random-effects meta-analysis of the 3 studies, which reported risk of incidence of uveitis in psoriasis patients compared to non-psoriasis controls, found a pooled risk ratio of 1.29 (95% CI, 1.10-1.51), indicating an increased risk of uveitis in psoriasis. Three studies compared risk of uveitis in psoriatic arthritis with psoriasis-only participants, all finding that psoriatic arthritis was associated with a greater risk of uveitis. Conclusions In summary, our findings suggest that psoriasis is associated with an increased risk of uveitis, with or without psoriatic arthritis.

show abstract

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

et al. 2020

View full text Add to dashboard Cite

show abstract

Immune-Mediated Inflammatory Diseases and Other Comorbidities in Patients With Psoriasis: Baseline Characteristics of Patients in the AQUILES Study

Abstract: In patients with psoriasis the prevalence of other IMIDs was 15.5%, a level slightly higher than that found in the general population. Nearly three-quarters of these patients had at least 1 cardiovascular risk factor.

Cited by 11 publications

References 33 publications

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis

The Incidence and Prevalence of Uveitis in Psoriasis: A Systematic Review and Meta-Analysis

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

Contact Info

Product

Resources

About